Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study
- 5 June 2019
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 37 (26), 3485-3494
- https://doi.org/10.1016/j.vaccine.2019.03.059
Abstract
No abstract availableFunding Information
- Australian National Health and Medical Research Council (GNT1099183)
- UK Global Challenges Research Fund
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
This publication has 55 references indexed in Scilit:
- Detection of group a streptococcal pharyngitis by quantitative PCRBMC Infectious Diseases, 2013
- Experimental Human Pneumococcal CarriageJournal of Visualized Experiments, 2013
- Large-Scale Validation of the Centor and McIsaac Scores to Predict Group A Streptococcal PharyngitisJAMA Internal Medicine, 2012
- Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus CaseMolecular & Cellular Proteomics, 2012
- Invasive Group A Streptococcal DiseaseDrugs, 2012
- Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later lifeKidney International, 2012
- World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guidelineNature Reviews Cardiology, 2012
- New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococciVaccine, 2011
- Staphylococcus aureusis the most common identified cause of cellulitis: a systematic reviewEpidemiology and Infection, 2009
- Burden and Economic Cost of Group A Streptococcal PharyngitisPEDIATRICS, 2008